Advertisement

Current Oncology Reports

, 21:95 | Cite as

When Can We Avoid Postmastectomy Radiation Following Primary Systemic Therapy?

  • Ángel Montero
  • Raquel Ciérvide
  • Philip PoortmansEmail author
Breast Cancer (B Overmoyer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Breast Cancer

Abstract

Purpose of Review

Postmastectomy radiation therapy (PMRT) has been shown to reduce the risk of locoregional recurrences (LRR) and of distant metastases (DM) and to improve breast cancer–specific survival (BCSS) as well as overall survival (OS) in patients with locally advanced breast cancer who are considered high risk because of large tumors (> 5 cm) and/or presence of axillary lymph node involvement.

Recent Findings

Controversy is still ongoing with respect to the indication of PMRT in the case of earlier stage invasive tumors in the presence of risk factors including young age, premenopausal status, presence of lymphovascular invasion (LVI), high tumor grade, or tumor size 2–5 cm. Simultaneously, the evolution of our understanding of breast cancer biology has led us to better identify patients for whom the administration of systemic treatment prior to surgery reduces tumor load, not only in the case of locally advanced tumors but also for earlier stages, namely in the case of unfavorable molecular subtypes. The role of PMRT in the context of these patients treated with primary systemic therapy (PST), especially after a good tumor response, is under evaluation by various studies.

Summary

This review identifies factors that may permit PMRT omission in a selected group of patients after PST.

Keywords

Breast cancer Mastectomy Postmastectomy radiation therapy Primary systemic therapy Lymph node irradiation 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97(2):116–26.PubMedGoogle Scholar
  2. 2.
    Overgaard M, Hansen PS, Overgaard J, Carsten R, Andersson M, Bah F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 1997;337:949–55.PubMedGoogle Scholar
  3. 3.
    Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–8.PubMedGoogle Scholar
  4. 4.
    Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82(3):247–53.PubMedGoogle Scholar
  5. 5.
    Li Y, Moran MS, Huo Q, Yang Q, Haffty BG. Post-mastectomy radiotherapy for breast cancer patients with T1-T2 and 1-3 positive lymph nodes: a meta-analysis. PLoS One. 2013;8(12):1–9.Google Scholar
  6. 6.
    Poortmans P. Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate. Lancet. 2014;383(9935):2104–6.PubMedGoogle Scholar
  7. 7.
    Johnson ME, Handorf EA, Martin JM, Hayes SB. Postmastectomy radiation therapy for T3N0: a SEER analysis. Cancer. 2014;120(22):3569–74.PubMedPubMedCentralGoogle Scholar
  8. 8.
    • Francis SR, Frandsen J, Kokeny KE, Gaffney DK, Poppe MM. Outcomes and utilization of postmastectomy radiotherapy for T3N0 breast cancers. Breast. 2017;32:156–61 A review based upon NCDB data focused on the use of PMRT in large and negative lymph nodes breast tumors (T3N0) suggesting survival advantage. PubMedGoogle Scholar
  9. 9.
    • Cassidy RJ, Liu Y, Kahn ST, Jegadeesh NK, Liu X, Subhedar PD, et al. The role of postmastectomy radiotherapy in women with pathologic T3N0M0 breast cancer. Cancer. 2017;54(PROC):1–2 Based upon data from NCDB (National Cancer Database), this review confirms benefit in overall survival with PMRT in pT3N0 tumors. Google Scholar
  10. 10.
    Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007 Oct;94(10):1189–200.PubMedGoogle Scholar
  11. 11.
    Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes. JAMA Oncol. 2016;2(6):751–60.PubMedGoogle Scholar
  12. 12.
    Li J, et al. Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy. Oncotarget. 2017;8(11):18399–408.PubMedGoogle Scholar
  13. 13.
    • Wang-Lopez Q, et al. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer? Crit Rev Oncol Hematol. 2015;95(1):88–104 Pathologic complete response (pCR) after PST has been suggested to be predictive of survival in breast cancer, although this fact remains a subject of controversy. This well-presented review addresses on the importance of an adequate definition of pCR and its significance in breast cancer outcomes. PubMedGoogle Scholar
  14. 14.
    Glück S, de Snoo F, Peeters J, Stork-Sloots L, Somlo G. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013 Jun;139(3):759–67. doi:10.1007/s10549-013-2572-4.PubMedGoogle Scholar
  15. 15.
    Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.PubMedGoogle Scholar
  16. 16.
    Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84.PubMedGoogle Scholar
  17. 17.
    Swain SM, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018;2017:646–53.Google Scholar
  18. 18.
    Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet Oncol. 2014;384:164–72.Google Scholar
  19. 19.
    Golshan M, Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg. 2015;262(3):434–8.PubMedPubMedCentralGoogle Scholar
  20. 20.
    • Chapman CH, Jagsi R. Postmastectomy radiotherapy after neoadjuvant chemotherapy: a review of the evidence. Oncology (Williston Park). 2015;29(9):657–66 This paper nicely reviews current evidence regarding PMRT use after PST and emphasizing the most controversial aspects and future directions . Google Scholar
  21. 21.
    Abdel-Wahab M, et al. The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer: a phase II trial of neoadjuvant MVAC, surgery, and radiation. Int J Radiat Oncol Biol Phys. 1998;40(4):875–80.PubMedGoogle Scholar
  22. 22.
    Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004;22(23):4691–9.PubMedGoogle Scholar
  23. 23.
    Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62(2):351–7.PubMedGoogle Scholar
  24. 24.
    McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SWC, Yu TK, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007;68(4):1004–9.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Sinn HP, et al. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd. 1994;54(10):552–8.PubMedGoogle Scholar
  26. 26.
    Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3(4):549–55.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18.PubMedGoogle Scholar
  28. 28.
    Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Boileau J-F, Poirier B, Basik M, Holloway CMB, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258–64.PubMedGoogle Scholar
  30. 30.
    Boughey JC, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2017;263(4):802–7.Google Scholar
  31. 31.
    Straver ME, Loo CE, Alderliesten T, Rutgers EJT, Peeters MTFDV. Marking the axilla with radioactive iodine seeds ( MARI procedure ) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer. Br J Surg. 2010;97:1226–31.PubMedGoogle Scholar
  32. 32.
    Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072–8.PubMedPubMedCentralGoogle Scholar
  33. 33.
    El H, et al. Refining the performance of sentinel lymph node biopsy post-neoadjuvant chemotherapy in patients with pathologically proven pre-treatment node-positive breast cancer : an update for clinical practice. Anticancer Res. 2016;1472:42–52.Google Scholar
  34. 34.
    Le Scodan R, et al. Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys. 2012;82(1):e1–7.PubMedGoogle Scholar
  35. 35.
    Nagar H, Mittendorf EA, Strom EA, Perkins GH, Oh JL, Tereffe W, et al. Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys. 2011;81(3):782–7.PubMedGoogle Scholar
  36. 36.
    Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol. 2012;30(32):3960–6.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Wright JL, Takita C, Reis IM, Zhao W, Saigal K, Wolfson A, et al. Predictors of locoregional outcome in patients receiving neoadjuvant therapy andpostmastectomy radiation. Cancer. 2013;119(1):16–25.PubMedGoogle Scholar
  38. 38.
    Diaz DA, Hurley J, Reis I, Takita C, Zhao W, Wright J. Locoregional outcomes in clinical stage IIB breast cancer after neoadjuvant therapy and mastectomy with or without radiation. Medicine (Baltimore). 2014;93(29):e230.Google Scholar
  39. 39.
    Shim SJ, Park W, Huh SJ, Choi DH, Shin KH, Lee NK, et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05). Int J Radiat Oncol Biol Phys. 2014;88(1):65–72.PubMedGoogle Scholar
  40. 40.
    Meattini I, Cecchini S, di Cataldo V, Saieva C, Francolini G, Scotti V, et al. Postmastectomy radiotherapy for locally advanced breast cancer receiving neoadjuvant chemotherapy. Biomed Res Int. 2014;2014:1–12.Google Scholar
  41. 41.
    Arsenault D, Hurley J, Takita C, Reis IM, Zhao W, Rodgers S, et al. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy. Am J Clin Oncol. 2015;38(4):348–52.PubMedGoogle Scholar
  42. 42.
    Yang TJ, et al. The effect of molecular subtype and residual disease on locoregional recurrence in breast cancer patients treated with neoadjuvant chemotherapy and postmastectomy radiation. Ann Surg Oncol. 2015;22(Suppl 3):S495–501.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Liu J, Mao K, Jiang S, Jiang W, Chen K, Kim BY, et al. The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB. Oncotarget. 2016;7(17):24848–59.PubMedGoogle Scholar
  44. 44.
    Rusthoven CG, Rabinovitch RA, Jones BL, Koshy M, Amini A, Yeh N, et al. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(5):818–27.Google Scholar
  45. 45.
    Huang L, Chen S, Yang WT, Shao Z. Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy. Oncotarget. 2017;8(24):39703–10.PubMedGoogle Scholar
  46. 46.
    • Gillon P, Touati N, Breton-Callu C, Slaets L, Cameron D, Bonnefoi H. Factors predictive of locoregional recurrence following neoadjuvant chemotherapyin patients with large operable or locally advanced breast cancer: an analysis of the EORTC 10994/BIG 1-00 study. Eur J Cancer. 2017;79:226–34 The results of this randomized, international and multicentre study confirm as factors directly related to the prognosis after PST both the unfavorable molecular subtype and the absence of pCR . PubMedGoogle Scholar
  47. 47.
    Rong QL, Wang SL, Tang Y, Jin J, Song YW, Wang WH, et al. The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy. Zhonghua Zhong Liu Za Zhi. 2017;39(6):445–52.PubMedGoogle Scholar
  48. 48.
    • Ohri N, et al. Postmastectomy radiation in breast cancer patients with pathologically positive lymph nodes after neoadjuvant chemotherapy: usage rates and survival trends. Int J Radiat Oncol Biol Phys. 2017;99(3):549–59 Using data from NCDB including nearly 30,000 patients, the authors analyze the role and usage of PMRT after PST in patients ypN+ . PubMedPubMedCentralGoogle Scholar
  49. 49.
    Cao L, et al. Outcome of postmastectomy radiotherapy after primary systemic treatment in patients with clinical T1-2N1 breast cancer. Cancer Radiother. 2018;22(1):38–44.PubMedGoogle Scholar
  50. 50.
    Chen X, Xia F, Luo J, Ma J, Yang Z, Zhang L, et al. Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II-III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy. Onco Targets Ther. 2018;11:1973–80.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Beriwal S, Shinde A, Rajagopalan MS, Kannan N, Heron DE, Deutsch M. Recommendations for post-mastectomy radiation therapy after neo-adjuvant chemotherapy: an international survey of radiation oncologists. Breast J. 2013;19(6):683–4.PubMedGoogle Scholar
  52. 52.
    Fowble BL, Einck JP, Kim DN, McCloskey S, Mayadev J, Yashar C, et al. Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. Int J Radiat Oncol Biol Phys. 2012;83(2):494–503.PubMedGoogle Scholar
  53. 53.
    Kantor O, Pesce C, Singh P, Miller M, Tseng J, Wang CH, et al. Post-mastectomy radiation therapy and overall survival after neoadjuvant chemotherapy. J Surg Oncol. 2017;115(6):668–76.PubMedGoogle Scholar
  54. 54.
    Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, et al. T3 disease at presentation or pathologic involvement of four or more lymph nodespredict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(1):138–45.PubMedGoogle Scholar
  55. 55.
    Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized. J Clin Oncol. 2004;22(21):4247–54.PubMedGoogle Scholar
  56. 56.
    Truong PT, Olivotto IA, Kader HA, Panades M, Speers CH, Berthelet E. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61(5):1337–47.PubMedGoogle Scholar
  57. 57.
    NCT01872975, NSABP B51/Radiation Therapy Oncology Group (RTOG). Standard or comprehensive radiation therapy in treating patients with early-stage breast cancer previously treated with chemotherapy and surgery, 2019.Google Scholar
  58. 58.
    NCT01901094, ALLIANCE A011202. Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy, 2019.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Ángel Montero
    • 1
  • Raquel Ciérvide
    • 1
  • Philip Poortmans
    • 2
    • 3
    Email author
  1. 1.Department of Radiation OncologyUniversity Hospital HM SanchinarroMadridSpain
  2. 2.Department of Radiation OncologyInstitut CurieParis Cedex 05France
  3. 3.Paris Sciences et Lettres - PSL UniversityParisFrance

Personalised recommendations